New Zealand’s Pharmaceutical Management Agency PHARMAC has announce the approval of an agreement with the local subsidiary of Ireland-incorporated drugmaker Allergan (NYSE: AGN) to amend the contractual terms of listing for clostridium botulinum type A toxin ( Botox (external link) ), inj 100 u vial in DHB hospitals.
Botox is used to treat medical conditions associated with overactive muscles including
overactive bladder with leakage of urine (urinary incontinence).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze